Published in J Clin Psychiatry on November 01, 2004
Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev (2008) 1.47
Transition to mania during treatment of bipolar depression. Neuropsychopharmacology (2010) 0.95
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) (2013) 0.86
The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. Neuropsychiatr Dis Treat (2006) 0.83
Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases. Clin Psychopharmacol Neurosci (2013) 0.76
Medical treatment and weight gain. Prev Chronic Dis (2007) 0.75
Repeated activation of mania by atypical antipsychotics in a patient. BMJ Case Rep (2012) 0.75
Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res (2002) 3.31
Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry (2005) 1.89
Lithium monitoring by reverse iontophoresis in vivo. Clin Chem (2004) 1.47
Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology (2005) 1.23
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med (2012) 1.19
Efficacy of psychoeducational approaches on bipolar disorders: a review of the literature. J Affect Disord (2006) 1.13
Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system. J Affect Disord (2009) 1.11
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs (2009) 1.07
Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs (2009) 1.05
Screening for bipolar disorders using a French version of the Mood Disorder Questionnaire (MDQ). J Affect Disord (2005) 1.00
Motivations to play specifically predict excessive involvement in massively multiplayer online role-playing games: evidence from an online survey. Eur Addict Res (2011) 1.00
Early telephone intervention for psychiatric outpatients starting antidepressant treatment. Nord J Psychiatry (2010) 0.99
Retracted Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder. Br J Psychiatry (2013) 0.97
The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. J Psychiatr Res (2006) 0.97
Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder. CNS Drugs (2009) 0.96
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit (2008) 0.95
Wearable monitoring for mood recognition in bipolar disorder based on history-dependent long-term heart rate variability analysis. IEEE J Biomed Health Inform (2013) 0.94
Mindful Attention Awareness Scale (MAAS): Psychometric properties of the French translation and exploration of its relations with emotion regulation strategies. Psychol Assess (2009) 0.94
Complex interaction of circadian and non-circadian effects of light on mood: shedding new light on an old story. Sleep Med Rev (2012) 0.92
The neural substrates of social emotion perception and regulation are modulated by adult attachment style. Soc Neurosci (2012) 0.91
Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol (2003) 0.90
Quality of Web-based information on depression. Depress Anxiety (2010) 0.90
Quality of web-based information on pathological gambling. J Gambl Stud (2008) 0.89
Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One (2013) 0.88
Affective response to a loved one's pain: insula activity as a function of individual differences. PLoS One (2010) 0.88
Mental disorders in offspring of parents with bipolar and major depressive disorders. Bipolar Disord (2012) 0.87
Smoking in psychiatric inpatients: association with working status, diagnosis, comorbid substance abuse and history of suicide attempts. Addict Behav (2009) 0.87
No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects. Biol Psychiatry (2006) 0.87
Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression? Pharmacol Res (2008) 0.86
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics (2011) 0.86
Speech analysis for mood state characterization in bipolar patients. Conf Proc IEEE Eng Med Biol Soc (2012) 0.85
Plasma corticosterone, dexamethasone (DEX) suppression and DEX/CRH tests in a rat model of genetic vulnerability to depression. Psychoneuroendocrinology (2007) 0.85
Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. JAMA Psychiatry (2013) 0.85
Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res (2012) 0.84
Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode. J Psychiatr Res (2004) 0.83
Salivary cortisol profiles in patients remitted from recurrent depression: one-year follow-up of a mindfulness-based cognitive therapy trial. J Psychiatr Res (2011) 0.83
Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol (2013) 0.82
Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.82
Time course of response to paroxetine: influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.81
Effects of olanzapine and quetiapine on corticotropin-releasing hormone release in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.81
Affective temperaments in alcohol and opiate addictions. Psychiatr Q (2013) 0.81
Clinical state assessment in bipolar patients by means of HRV features obtained with a sensorized T-shirt. Conf Proc IEEE Eng Med Biol Soc (2012) 0.81
Effects of emotional contexts on cerebello-thalamo-cortical activity during action observation. PLoS One (2013) 0.81
Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia? J Nerv Ment Dis (2009) 0.80
The cortisol awakening response in patients remitted from depression. J Psychiatr Res (2010) 0.79
Assessment of mindfulness with the French version of the Kentucky Inventory of Mindfulness Skills in community and borderline personality disorder samples. Assessment (2010) 0.79
Impact of the life goals group therapy program for bipolar patients: an open study. J Affect Disord (2006) 0.79
A retrospective comparison of inpatients with mixed and pure depression. Psychopathology (2003) 0.78
Melatonin in treatment of chronic sleep disorders in adults with autism: a retrospective study. Swiss Med Wkly (2009) 0.78
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression. World J Biol Psychiatry (2006) 0.77
CBT/DBT skills training for adults with attention deficit hyperactivity disorder (ADHD). Psychiatr Danub (2016) 0.77
Neural substrates of cognitive switching and inhibition in a face processing task. Neuroimage (2013) 0.77
Performance of the Mood Disorder Questionnaire (MDQ) according to bipolar subtype and symptom severity. Eur Psychiatry (2009) 0.77
The efficiency of a carbamazepine-mianserin combination scheme in opiate detoxification. Hum Psychopharmacol (2004) 0.77
Phenomenology of racing and crowded thoughts in mood disorders: a theoretical reappraisal. J Affect Disord (2009) 0.76
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharmacogenet Genomics (2015) 0.76
Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments. J Clin Psychopharmacol (2015) 0.76
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. Pharmacogenet Genomics (2016) 0.76
A three-dimensional model of thoughts: insight into depression. Psychopathology (2012) 0.76
Risk of mental disorders in children of parents with alcohol or heroin dependence: a controlled high-risk study. Eur Addict Res (2012) 0.76
Subjective experience of thought overactivation in mood disorders: beyond racing and crowded thoughts. Psychopathology (2013) 0.76
Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol (2000) 0.76
Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol (2002) 0.75
Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study. Atten Defic Hyperact Disord (2015) 0.75
Missed Monday appointments. Psychiatr Serv (2005) 0.75
Effects of expertise on football betting. Subst Abuse Treat Prev Policy (2012) 0.75
Cognitive behaviour therapy reduces long term risk of relapse in recurrent major depressive disorder. Evid Based Ment Health (2005) 0.75
[Electroconvulsive therapy: thoughts on a prohibited treatment]. Rev Med Suisse (2008) 0.75